Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103407 | 0.94 | LMNA (0.50) | LMNAAKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL102280 | 0.88 | LMNA (0.50) | LMNAMAPTAKR1B1MEN1KMT2A | |
| SCHEMBL4317934 | 0.86 | LMNA (0.46) | LMNAAKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL104120 | 0.82 | LMNA (0.47) | LMNAAKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL101672 | 0.82 | LMNA (0.47) | LMNAAKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL103988 | 0.73 | LMNA (0.47) | LMNAAKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL542293 | 0.73 | AKR1B10 (0.39) | LMNAAKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL1091785 | 0.73 | LMNA (0.47) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL542424 | 0.73 | POLB (0.40) | LMNAAKR1B10MAPTAKR1A1AKR1B1 | |
| SCHEMBL542638 | 0.73 | AKR1B10 (0.39) | LMNAAKR1B10MAPTAKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | LMNA 1674/4885L3MBTL1 2025/4885AKR1B10 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.